PRMT5 and neoplasm: The inhibition of tumour growth upon T1-44 treatment coincided with a reduced level of the PRMT5 symmetric-dimethyl (SDMe) mark within colon26 tumour biopsies (Fig. 1E), thus confirming catalytic inhibition of PRMT5 in treated mice.